Issue

Vol. 19 (2027)

Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma

https://doi.org/10.1007/s40820-026-02320-7
Yanbing Cao
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Xinyi Lin
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Bingchen Wu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Yang Li
State Key Laboratory of Structural Chemistry & CAS Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, People’s Republic of China
Wenrui Zhu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Binxin Liu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Aixian Zheng
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Lingjie Wu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Yanyang Wang
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan 750004, People’s Republic of China
Xiaolong Liu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China
Ming Wu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China

Corresponding Author: Ming Wu

wmmj0419@163.com

Nano-Micro Letters, Vol. 19 (2027), Article Number: 9

Abstract

Hepatocellular carcinoma (HCC) responds poorly to immune checkpoint blockade, largely because of an immunologically cold tumor microenvironment (TME) characterized by deficient antigen presentation and impaired cytotoxic T cell responses. Analysis of numerous HCC clinical cohorts, including our institutional datasets, reveals that stimulator of interferon genes (STING) pathway activity is positively correlated with patient survival, enhanced antigen presentation capacity, and an immune-activated TME. However, achieving effective and controllable STING activation in immune-cold HCC tumors remains challenging. Here, we develop a biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC. A coordination nanomedicine MCI-NP is engineered by co-encapsulating the STING agonist MSA-2 and indocyanine green (ICG) via Cu2+-mediated chelation, enabling stabilized PTT-induced immunogenic cell death together with robust STING-driven innate immune activation. Further cloaked with PD-1-overexpressing cell membranes, MCI-NP@mPD-1 achieves an approximately fivefold increase in tumor accumulation compared with uncoated MCI-NP and enables localized PD-1/PD-L1 axis blockade. Following a single treatment, MCI-NP@mPD-1-based photothermal immunotherapy effectively suppresses primary tumor growth and significantly prolongs survival by remodeling the TME toward an immune-active state, while inducing durable systemic immune memory that effectively limited postoperative lung metastasis. Without introducing additional nanocarriers or excipients, MCI-NP@mPD-1 offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.


Highlights:
1 Clinical cohort analyses identify stimulator of interferon genes (STING) signaling as a key determinant of immune responsiveness in hepatocellular carcinoma (HCC), providing a data-driven rationale for nanomedicine design.
2 A carrier-free coordination nanomedicine co-assembles MSA-2 and indocyanine green to couple photothermal-induced immunogenic cell death with STING activation, while PD-1 membrane camouflage enables ~fivefold tumor accumulation and localized checkpoint blockade.
3 This integrated strategy converts immune-cold HCC into an immune-active state, achieving durable tumor control and systemic immune memory against metastasis.

Keywords

Hepatocellular carcinoma STING agonist Photothermal therapy Biomimetic nanomedicine Immune checkpoint blockade
Cao, Yanbing, Xinyi Lin, Bingchen Wu, Yang Li, Wenrui Zhu, Binxin Liu, Aixian Zheng, Lingjie Wu, Yanyang Wang, Xiaolong Liu, and Ming Wu. 2026. “Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma”. Nano-Micro Letters 19 (July):9. https://doi.org/10.1007/s40820-026-02320-7.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. L. Rimassa, R.S. Finn, B. Sangro, Combination immunotherapy for hepatocellular carcinoma. J. Hepatol. 79(2), 506–515 (2023). https://doi.org/10.1016/j.jhep.2023.03.003
  2. J.M. Llovet, F. Castet, M. Heikenwalder, M.K. Maini, V. Mazzaferro et al., Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19(3), 151–172 (2022). https://doi.org/10.1038/s41571-021-00573-2
  3. K.Y. Shen, Y. Zhu, S.Z. Xie, L.X. Qin, Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J. Hematol. Oncol. 17(1), 25 (2024). https://doi.org/10.1186/s13045-024-01549-2
  4. F. Foerster, S.J. Gairing, S.I. Ilyas, P.R. Galle, Emerging immunotherapy for HCC: a guide for hepatologists. Hepatology 75(6), 1604–1626 (2022). https://doi.org/10.1002/hep.32447
  5. M. Wu, Z. Luo, Z. Cai, Q. Mao, Z. Li et al., Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma. EMBO Mol. Med. 15(10), EMMM202216836 (2023). https://doi.org/10.15252/emmm.202216836
  6. K. Li, X. Yu, Y. Xu, H. Wang, Z. Liu et al., Cascaded immunotherapy with implantable dual-drug depots sequentially releasing STING agonists and apoptosis inducers. Nat. Commun. 16(1), 1629 (2025). https://doi.org/10.1038/s41467-025-56407-7
  7. K.M. Garland, T.L. Sheehy, J.T. Wilson, Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy. Chem. Rev. 122(6), 5977–6039 (2022). https://doi.org/10.1021/acs.chemrev.1c00750
  8. D. Liu, S. Liang, K. Ma, Q.F. Meng, X. Li et al., Tumor microenvironment‐responsive nanops amplifying STING signaling pathway for cancer immunotherapy. Adv. Mater. 36(6), 2304845 (2024). https://doi.org/10.1002/adma.202304845
  9. J. Yang, Z. Luo, J. Ma, Y. Wang, N. Cheng, A next-generation STING agonist MSA-2: from mechanism to application. J. Controlled Release 371, 273–287 (2024). https://doi.org/10.1016/j.jconrel.2024.05.042
  10. W. Zeng, Z. Li, Q. Huang, C. Ding, L. Yang et al., Multifunctional mesoporous polydopamine‐based systematic delivery of STING agonist for enhanced synergistic photothermal‐immunotherapy. Adv. Funct. Mater. 34(1), 2307241 (2023). https://doi.org/10.1002/adfm.202307241
  11. B.-S. Pan, S.A. Perera, J.A. Piesvaux, J.P. Presland, G.K. Schroeder et al., An orally available non-nucleotide STING agonist with antitumor activity. Science 369(6506), eaba6098 (2020). https://doi.org/10.1126/science.aba6098
  12. J. Gao, Q. Wu, Y. Yan, M. Chen, Q. Li et al., Second near‐infrared phototheranostics with cGAS‐STING‐activating capacity for photothermal immunotherapy. Adv. Funct. Mater. 34(34), 2401830 (2024). https://doi.org/10.1002/adfm.202401830
  13. X. Li, S. Khorsandi, Y. Wang, J. Santelli, K. Huntoon et al., Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nat. Nanotechnol. 17(8), 891–899 (2022). https://doi.org/10.1038/s41565-022-01134-z
  14. P. Xue, T. Bai, H. Zhuang, A.H. All, S. Yan et al., Cholesterol metabolism regulated nanoliposome ameliorates chemo/photothermal therapy reversing CD8(+) T cell exhaustion. Exploration 6(1), 20240123 (2026). https://doi.org/10.1002/EXP.20240123
  15. X. Lin, X. Wang, J. Li, L. Cai, F. Liao et al., Localized NIR-II photo-immunotherapy through the combination of photothermal ablation and in situ generated interleukin-12 cytokine for efficiently eliminating primary and abscopal tumors. Nanoscale 13(3), 1745–1758 (2021). https://doi.org/10.1039/d0nr06182d
  16. X. Lin, F. Li, Q. Gu, X. Wang, Y. Zheng et al., Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy. Acta Biomater. 146, 406–420 (2022). https://doi.org/10.1016/j.actbio.2022.04.029
  17. H. Wu, L. Gu, J. Xu, C. Zhang, M. Wang et al., Immunosuppressive microenvironment reprogramming by synergistic sonodynamic therapy of phthalocyanine-MOF hybrids for hepatocellular carcinoma. Exploration 6(2), 20250074 (2026). https://doi.org/10.1002/EXP.20250074
  18. A. Han, M. Liu, S. Li, Z. Gong, L. Tian et al., Design and clinical advances of smart photoresponsive systems in cancer theranostics. Coord. Chem. Rev. 552, 217548 (2026). https://doi.org/10.1016/j.ccr.2025.217548
  19. M. Wu, Q. Wang, D. Zhang, N. Liao, L. Wu et al., Magnetite nanocluster@poly (dopamine)-PEG@ indocyanine green nanobead with magnetic field-targeting enhanced MR imaging and photothermal therapy in vivo. Colloids Surf. B Biointerfaces 141, 467–475 (2016). https://doi.org/10.1016/j.colsurfb.2016.02.022
  20. X. Huang, Y. Lu, M. Guo, S. Du, N. Han, Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view. Theranostics 11(15), 7546 (2021). https://doi.org/10.7150/thno.56482
  21. H. Zhao, J. Xu, C. Feng, J. Ren, L. Bao et al., Tailoring aggregation extent of photosensitizers to boost phototherapy potency for eliciting systemic antitumor immunity. Adv. Mater. 34(8), 2106390 (2022). https://doi.org/10.1002/adma.202106390
  22. Y. Xia, S. Fu, Q. Ma, Y. Liu, N. Zhang, Application of nano‑delivery systems in lymph nodes for tumor immunotherapy. Nano-Micro Lett. 15(1), 145 (2023). https://doi.org/10.1007/s40820-023-01125-2
  23. X. Sun, Y. Zhang, J. Li, K.S. Park, K. Han et al., Amplifying STING activation by cyclic dinucleotide-manganese ps for local and systemic cancer metalloimmunotherapy. Nat. Nanotechnol. 16(11), 1260–1270 (2021). https://doi.org/10.1038/s41565-021-00962-9
  24. M. Huang, C. Xu, S. Yang, Z. Zhang, Z. Wei et al., Vehicle-free nanotheranostic self-assembled from clinically approved dyes for cancer fluorescence imaging and photothermal/photodynamic combinational therapy. Pharmaceutics 14(5), 1074 (2022). https://doi.org/10.3390/pharmaceutics14051074
  25. Y. Zhang, S. Yao, Y. Zhao, S. Zhu, W. Fang et al., STING agonist-modified tumor targeting photosensitizer remodels cancer-associated fibroblasts to potentiate photoimmunotherapy in pancreatic cancer. Adv. Sci. 13, e20547 (2025). https://doi.org/10.1002/advs.202520547
  26. M. Wu, C. Zhang, A. Zhong, H. Li, Y. Zhou et al., Systemic delivery of stealth adenoviral vector to reinvigorate antitumor immunity by PD-L1 genome editing and TIGIT/CD155 blockade. Fundam. Res. (2025). https://doi.org/10.1016/j.fmre.2025.04.015
  27. W. Peng, Y. Cao, Y. Zhang, A. Zhong, C. Zhang et al., Optimal irreversible electroporation combined with nano‐enabled immunomodulatory to boost systemic antitumor immunity. Adv. Healthc. Mater. 13(7), 2302549 (2024). https://doi.org/10.1002/adhm.202302549
  28. Y. Zhang, A. Zhong, J. Min, H. Tu, Y. Cao et al., Biomimetic responsive nanoconverters with immune checkpoint blockade plus antiangiogenesis for advanced hepatocellular carcinoma treatment. ACS Appl. Mater. Interfaces 16(6), 6894–6907 (2024). https://doi.org/10.1021/acsami.3c18140
  29. H. Tu, Y. Cao, X. Lin, L. Ding, Y. Zhou et al., Anti-PD-L1 biomimetic nanobubbles for ultrasound-triggered reprogramming of cold hepatocellular carcinoma for immunotherapy. J. Controlled Release 392, 114659 (2026). https://doi.org/10.1016/j.jconrel.2026.114659
  30. Y. Li, G. Liu, J. Ma, J. Lin, H. Lin et al., Chemotherapeutic drug-photothermal agent co-self-assembling nanops for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy. J. Controlled Release 258, 95–107 (2017). https://doi.org/10.1016/j.jconrel.2017.05.011
  31. X. Duan, Y. Zhao, H. Hu, X. Wang, J. Yan et al., Amino acid metabolism-regulated nanomedicine for enhanced tumor immunotherapy through synergistic regulation of immune microenvironment. Biomater. Res. 28, 0048 (2024). https://doi.org/10.34133/bmr.0048
  32. R.R. Anderson, J.A. Parrish, Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 220(4596), 524–527 (1983). https://doi.org/10.1126/science.6836297
  33. B. Zhu, F. Qu, D. Bi, R. Geng, S. Chen et al., Monolayer LDH nanosheets with ultrahigh ICG loading for phototherapy and Ca2+-induced mitochondrial membrane potential damage to co-enhance cancer immunotherapy. ACS Appl. Mater. Interfaces 15(7), 9135–9149 (2023). https://doi.org/10.1021/acsami.2c22338
  34. D.V. Krysko, A.D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis et al., Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12(12), 860–875 (2012). https://doi.org/10.1038/nrc3380
  35. N. Samson, A. Ablasser, The cGAS-STING pathway and cancer. Nat. Cancer 3(12), 1452–1463 (2022). https://doi.org/10.1038/s43018-022-00468-w
  36. Y. Wang, J. Luo, A. Alu, X. Han, Y. Wei et al., cGAS-STING pathway in cancer biotherapy. Mol. Cancer 19(1), 136 (2020). https://doi.org/10.1186/s12943-020-01247-w
  37. B. Wu, M. Song, Q. Dong, G. Xiang, J. Li et al., UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PD-L1 transcription in triple negative breast cancer. Theranostics 12(11), 5086 (2022). https://doi.org/10.7150/thno.74989
  38. S. Ning, P. Shangguan, X. Zhu, X. Ou, K. Wang et al., Pyridinium rotor strategy toward a robust photothermal agent for STING activation and multimodal image-guided immunotherapy for triple-negative breast cancer. J. Am. Chem. Soc. 147(9), 7433–7444 (2025). https://doi.org/10.1021/jacs.4c15534
Read More
Author biographies are not available.
Download this PDF file
PDF SUPPLEMENTARY FILE

Most read articles by the same author(s)

<< < 1 2 3